The science behind AB-KOLICARE®

How AB-KOLICARE® helps

AB-KOLICARE isn’t just any probiotic — it’s backed by solid clinical evidence showing real, fast results for babies with colic and digestive discomfort. Here’s what the studies tell us:

Faster colic relief than leading probiotics

In a clinical study, AB-KOLICARE worked faster than L. reuteri Protectis, with most babies feeling better and crying less after just 7 days of treatment.

-150min/day

less crying and fussing

Effective for both breastfed and formula-fed babies

No matter how your baby is fed, AB-KOLICARE® has been proven to relieve colic symptoms — making it a reliable choice for all families.

9 of 10babies

respond within 2 weeks

Reduces parental stress

Parents reported less anxiety and more peace of mind after using AB-KOLICARE®, thanks to visible improvements in their baby’s comfort.

63% lessparental anxiety

after 2 weeks

Improves gut health

Clinical trials showed that AB-KOLICARE® increases the good bacteria (bifidobacteria) in the gut, supporting a balanced, healthy microbiota that’s crucial for digestion and immunity.

15% moregood bacteria

Safe, natural, and scientifically proven

Tested in more than 300 infants across multiple studies, AB-KOLICARE® has shown excellent results without side effects.

Zeroreported side effects

in clinical trials

How to Use

Discover our Clinical Studies

If you’re curious about the research behind these claims, you can explore a summary of the clinical trials and published results.

Get in Touch

References

  1. Moreno-Villares, J. M. et al. Comparative efficacy of probiotic mixture Bifidobacterium longum KABP042 plus Pediococcus pentosaceus KABP041 vs. Limosilactobacillus reuteri DSM17938 in the management of infant colic: a randomized clinical trial. Eur J Pediatr 183, 5371–5381 (2024).
  2. Chen, K. et al. Infantile Colic Treated With Bifidobacterium longum CECT7894 and Pediococcus pentosaceus CECT8330: A Randomized, Double-Blind, Placebo-Controlled Trial. Front Pediatr 9, 939 (2021).
  3. Astó, E. et al. Probiotic Properties of Bifidobacterium longum KABP042 and Pediococcus pentosaceus KABP041 Show Potential to Counteract Functional Gastrointestinal Disorders in an Observational Pilot Trial in Infants. Front Microbiol 12, (2022).
  4. Santas J, Fuentes MC, Tormo R, Guayta-Escolies R, Lazaro E, C. J. Pediococcus pentosaceus CECT 8330 and bifidobacterium longum CECT 7894 show a trend towards lowering infantile excessive crying syndrome in a pilot clinical trial. Int J Pharma Bio Sci 6, 458–466 (2015).
  5. Tintore M, C. J. Probiotic treatment with AB-KOLICARE causes changes in the microbiota which correlate with a reduction in crying time. Int J Pharma Bio Sci 8, 281–288 (2017).
  6. Alcántara, C. et al. Study of the biosynthesis and functionality of polyphosphate in Bifidobacterium longum KABP042. Scientific Reports 2023 13:1 13, 1–13 (2023).
  7. Dong, F. et al. Pediococcus pentosaceus CECT 8330 protects DSS-induced colitis and regulates the intestinal microbiota and immune responses in mice. J Transl Med 20, 1–16 (2022).